The Global Metastatic cancer treatment market is anticipated to grow at a CAGR of 7.13% between 2018 and 2026. A metastasis or metastatic cancer is the spread of cancer cells from the place where they first formed to another part of the body. The Metastatic cancer treatment market is primarily driven by the following factors:

• Rising prevalence of cancer
• Increasing prevalence and awareness about metastatic cancer
• Growing R&D in the field of oncology
• Rising ageing population
• Advancements in research & development
• Promised potential of alternative therapies

The important drivers increasing growth in the global metastatic cancer treatment market include the rising prevalence of cancer and the increasing prevalence and awareness about metastatic cancer. Cancer has a major impact on society as it is one of the leading causes of morbidity and mortality. WHO estimated that there are about 14 million new cancer cases globally each year and the trend is only getting worse. Campaigns involving T.V., film, media and sports stars have contributed significantly to raising the profile of the issue amongst the general populations and have raised the level of awareness about cancer.

The Therapeutic indications of metastatic cancer treatment market are used extensively for various purposes. Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumours, secondary, or stage IV breast cancer; is a stage of breast cancer where the disease has spread to distant sites beyond the axillary lymph nodes. Metastatic prostate cancer develops when the abnormal cells of the prostate cancer increase in an unrestrained way and extend outside the prostate into distant or nearby shares of the body. Local metastasis of lung cancer into nerves causes shoulder pain, into oesophagus causes dysphagia, and into bone causes pain and swelling. Melanoma is the rarest form of skin cancer that arises from the pigment-producing cells known as the melanocytes. Colorectal cancer can become metastatic if cancer tends to grow into the blood vessels or lymph vessels and from there to nearby lymph nodes or to distant parts of the body. Other common types of cancer include stomach cancer, kidney cancer, bladder cancer, pancreatic cancer, gallbladder cancer and all.

Adverse side effects of chemotherapy and reimbursement issue are the major factors hindering the metastatic cancer treatment market. Although chemotherapy is considered to be one of the best ways to treat advanced cancer cells, it is often associated with a number of adverse side effects. Third-party payors are often reluctant to reimburse healthcare providers for new and innovative technologies or drugs.

The global metastatic cancer treatment market segments include therapeutic indication and products.

Therapeutic indications are segmented into:

• Breast cancer
• Prostate cancer
• Lung cancer
• Melanoma
• Colorectal cancer
• Other therapeutic applications

Products are segmented into:

• Branded medicines
• Generic medicines

This report covers the present market conditions and the growth prospects of the global metastatic cancer treatments market for 2018-2026 and considered the revenue generated through the sales of the metastatic cancer treatments for Therapeutic indication and products to calculate the market size by considering 2017 as the base year.

Geographically, the global metastatic cancer treatments market has been segmented on the basis of four major regions, which include:

• North America: The United States & Canada
• Asia-Pacific: China, India, Japan, Australia, South Korea & Rest of APAC
• Europe: The United Kingdom, France, Germany, Italy, Spain, Russia and Rest of Europe
• Rest of World: Latin America & Middle East and Africa

The Metastatic cancer treatment market in North America is expected to hold the largest share by 2026 owing to the rising incidence of various types of cancers, growing geriatric population, technological advancement in new drug discovery and support of the government. North America majorly comprises of the U.S. and the Canadian market. Currently, the U.S. accounts for the largest share as a result of extensive investments, by government organizations and pharmaceutical companies, in terms of research and discovery of innovative oncology drugs for the treatment of metastatic cancer. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the metastatic cancer treatment market. Ageing populations, changes in lifestyle, increased exposure to cancer-causing mutagens and other genetic factors, are some of the common risk factors associated with the economic development and epidemiologic transition of the Asia-Pacific region. As a result of this, the high-income countries, such as Japan, the Republic of Korea, and Singapore, are developing and implementing national cancer control programs to arrest this life-threating condition.

The metastatic cancer treatment market is segmented on the basis of products which are sub-divided into branded medicines and generic medicines. Branded drugs are the drugs that are originally discovered, developed, and commercialized by a pharmaceutical company. Several companies are investing a huge amount of money for research and development of innovative oncology medicines under their own brand name. Approved generic oncology drugs are as safe and effective as their brand-name counterparts. Before a generic drug is approved for commercialization, several regulatory authorities, such as the FDA, checks its pharmaceutical equivalence and bioequivalence with respect to the original branded version.

The major market players of the global metastatic cancer treatment market are:

• Eli Lilly And Company
• Bristol-Myers Squibb
• Novartis Ag
• Pfizer, Inc.
• Hoffmann-La Roche Ltd

Company Profiles covers analysis of important players.

Eli Lilly’s oncology products include Alimta, indicated for the first-line treatment, in combination with another agent, of advanced non-small cell lung cancer for patients with non-squamous cell histology; for the second-line treatment of advanced non-squamous NSCLC; as monotherapy for the maintenance treatment of advanced non-squamous NSCLC in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent, for the treatment of malignant pleural mesothelioma.  Another company, F. Hoffmann-La Roche Ltd (Roche or ‘the group’) is one of the leading healthcare groups, focused on the discovery and development, manufacturing and marketing of innovative therapeutic and diagnostic products.

Key Findings of the global metastatic cancer treatment market:

• Breast cancer therapeutic indication is majorly used
• Generic medicines are anticipated to grow at a significant rate
• Melanoma is the most prevailing cancer